Studies have demonstrated that patients with liver fibrosis and cirrhosis exhibit increased levels of IL-17, which positively correlate with advanced stages of liver disease, including the development of hepatocellular carcinoma [13]. Here, IL17A is linked to hepatocellular carcinoma.